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A B S T R A C T
Background. Pre-transplant donor-specific anti-human leukocyte antigen antibodies (DSAs) are known risk factors for acute rejection and reduced graft survival after kidney transplantation. DSAs may also develop de novo DSAs (dnDSAs) after transplantation but the clinical implications of these antibodies remain uncertain. Methods. We undertook a systematic review of observational studies that examined the association between dnDSAs and graft and patient outcomes (through August 2017) with the Conclusions. dnDSAs are associated with increased risks of adverse graft and patient outcomes after kidney transplantation, but estimation uncertainty of the augmented risks exist due to limitations such as heterogeneity within the existing literature. Therapeutic interventions targeted to eliminate or prevent these antibodies evaluated in randomized controlled trials are needed to establish whether dnDSAs are causal to transplantation outcomes.
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I N T R O D U C T I O N
Acute and chronic rejections after kidney transplantation are major impediments to long-term graft survival. Recipients who have experienced any type of acute rejection after kidney transplantation have a 50% increased risk of graft loss compared with those without, with the greatest risk in those with vascular and/or antibody-mediated rejection (AMR) [1] . The presence of pre-transplant donor-specific anti-human leukocyte antigen antibodies (DSAs) is a risk factor for early rejection, particularly for AMR [2, 3] . Recipients with pre-formed DSAs are nearly twice as likely to experience AMR and graft loss compared with recipients without pre-formed antibodies [4] .
DSAs may also develop after transplantation (de novo) and are largely attributed to inadequate immunosuppression [5, 6] . Unlike pre-transplant DSAs, the impact of de novo DSAs (dnDSAs) on long-term graft and patient outcomes is unclear, with substantial variability in the reported excess risk associated with dnDSAs, ranging from 0 to 15 times for acute rejection and graft loss [7, 8] . In part, this variation may represent differences in methodologies used to detect antibodies, characteristics of the dnDSAs that develop or the follow-up time of the study. Recent data have also suggested that the detection of complementbinding dnDSAs such as C1q and C3d is associated with a 10-to 20-fold increase in risk of allograft loss [9, 10] .
The aims of this study were to quantify the association between dnDSAs and allograft and patient outcomes, and to identify the specific prognostic factors that may have the greatest clinical impact on dnDSAs and allograft outcomes.
M A T E R I A L S A N D M E T H O D S
The systematic review and meta-analysis were written and reported in adherence to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) [11] reporting criteria.
Inclusion/exclusion criteria
Cohort studies were included if they involved recipients of kidney (living or deceased and of any age) or kidney-pancreas transplants with all methodologies for testing of dnDSAs considered. Studies were only included if they reported data comparing clinical outcomes [acute cellular rejection, acute AMR, chronic AMR or transplant glomerulopathy (TG), graft failure/ survival rates and patient survival] for those with and without dnDSAs.
Case-control studies, editorials, reviews, letters, research supports, other non-primary study articles and those that included non-kidney transplants or multi-organ transplants (apart from kidney pancreas) were excluded. Studies without an appropriate comparator group (e.g. where all participants experienced graft loss) were also excluded as estimation of the association (relative risk) between the exposure and outcome requires testing for dnDSAs to have been conducted on recipients with and without the clinical events of interest.
Literature search
A comprehensive literature search of MEDLINE and Embase was conducted to source all relevant studies from inception until the end of August 2017, without language restriction. Non-English publications were translated and evaluated for eligibility where possible. Conference proceedings and abstracts were also evaluated and included if full texts were available. If more than one publication of a study was retrieved, articles with the most recent and complete information were included, although additional unique data from all sources were considered and included where relevant. Disagreement regarding study inclusion was resolved by consensus between two authors (J.R.L. and A.S.) and further discussion with a third (G.W.) if necessary. The detailed search strategy is shown in Supplementary Appendix 1.
Data extraction
Data on patient demographics, allograft characteristics, techniques and timing of antibody detection, incidence of acute cellular rejection (alone, mixed or unspecified), acute AMR (alone, mixed or unspecified), chronic AMR and TG, graft and patient survival were extracted. Data extraction was done independently for all studies by A.S. and J.R.L. with discrepancies resolved by discussion. Cohen's kappa analysis [12] was done to measure the initial level of agreement between the two reviewers. A kappa of >0.8 was considered good, 0.6-0.8 as substantial, 0.4-0.6 as moderate, 0.2-0.4 as fair and <0.2 as poor.
dnDSAs and renal transplant outcomes
Risk of bias assessment and level of evidence
The risk of bias for observational studies was evaluated using the Newcastle-Ottawa Scale (NOS) [13] . The following domains were assessed: representativeness of exposed cohort, ascertainment of exposure (dnDSAs development), statistical methods, outcomes of interest defined a priori (outcomes reporting bias), assessment of outcomes, follow-up times for outcomes and attrition.
The confidence that may be placed in the summary estimates was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) [14] . The following domains were considered: risk of bias/study limitations, consistency of prognostic estimates among studies (heterogeneity), publication bias, directness of evidence (generalizability) and precision of treatment estimates (width of confidence interval and impact on clinical significance). The GRADE system specifies four levels of certainty, namely, high quality (where further research is very unlikely to change our confidence in the estimate of effect); moderate (where further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate); low quality (where further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate); and very low quality (where any estimate of effect is very uncertain) evidence.
Statistical analysis and data synthesis
Where primary event data were reported in individual studies, risk ratios (RR) [with 95% confidence intervals (CI)] were calculated, from which a summary estimate was determined using DerSimonian and Laird random-effects models. Publication bias was assessed using funnel plots and the Egger's regression test. We evaluated for heterogeneity using the I 2 statistic and considered the I 2 thresholds of <25%, 25-49%, 50-75% and >75% to represent low, moderate, high and very high heterogeneity, respectively [15] . Meta-regression was conducted to explain between study heterogeneity and investigate for any specific predetermined factors that may affect the association between development of dnDSAs and graft outcomes. These factors included recipient age, recipient gender, donor type (living or deceased), proportion of first transplants, human leukocyte antigen (HLA) mismatches at transplantation, mean fluorescent index (MFI) threshold used to define dnDSAs positivity, HLA class of dnDSAs (Class I only, Class II only or mixed), study sample size, follow-up period, year of study publication and geographical region of study. Sensitivity analysis was performed using studies that exclusively employed LABScreen technology pre-and post-transplant to investigate the impact of antibody test methodology on the estimate of effects.
R E S U L T S

Characteristics of included studies
Of the 2125 potentially eligible publications identified, 36 studies (n ¼ 10 535) of 31 cohorts were eligible for inclusion (Table 1 and Figure 1 ). The inter-reviewer level of agreement regarding eligibility of included studies was good (OE ¼ 0.95). Most of the included studies were published in 2014 or later and represented cohorts of <500 recipients. Of the 31 studies of distinct cohorts, 39% (12/31) 
Risk of bias and level of evidence
The overall risk of bias due to study limitations was considered high for all included studies. Fifty-three percent (19/36) of studies enrolled a consecutive group of transplant recipients and the remaining studies (39%, 14/36) selected a subset of the general transplant population or did not provide a clear description of how the study population was identified and selected. Although most of the studies (78%, 28/36) provided a clear description of how the exposure (development of dnDSAs) was ascertained, there was significant between-study variation in the measurement of the exposure. Even when similar technology was used to screen for antibodies, the MFI thresholds defined for DSAs positivity varied from any positive MFI value to a MFI value above 2000. Similar variability was also observed for the frequency and timing of dnDSAs testing (Table 1 and  Supplementary data, Table S2 ). Only 11% (4/36) of the studies defined their outcomes of interests a priori. Most studies (86%, 31/36) provided descriptions of how outcomes such as acute AMR were assessed, but only 17% (6/36) reported adjustment for potential confounders such as baseline immunosuppression or HLA mismatches at time of transplantation. The adequacy of follow-up time post-transplant was assessed based on the outcomes the study reported (acute cellular rejection !1 year, other outcomes !5 years). Using these criteria, 47% (17/36) of studies had adequate follow-up times whereas another 50% (18/36) had limited follow-up time for the outcomes reported. Sixty-one percent (22/36) of studies did not provide descriptions of participants that were lost to follow-up or study design. Details of the risk of bias assessment are presented in Supplementary data, Figure S1 .
Due to the observational design of the included studies, the quality of evidence for all outcomes was downgraded to low and from here adjusted further according to the GRADE methodology. Table 2 summarizes the quality of evidence using the GRADE system of reporting with details of the assessment available in Supplementary data, Table S3 .
Clinical outcomes
Acute rejection: cellular rejection (30 studies, 7864 recipients), AMR (29 studies, 8857 recipients). Cellular rejection.
The proportion of recipients with dnDSAs who experienced acute cellular rejection varied between 6 and 83% for (n ¼ 13) studies with a median follow-up <5 years, and between 14 and 78% for (n ¼ 9) studies with a median study followup !5 years. Overall, recipients with dnDSAs experienced an increased risk of acute cellular rejection [RR 2.92; 95% CI 2.16-3.94, I 2 ¼ 76%, 22 studies, n ¼ 4991, no evidence of publication bias (Egger's regression intercept P ¼ 0.245)] compared with recipients without dnDSAs (Figure 2 ). The quality of evidence for acute cellular rejection was graded as low.
AMR.
The proportion of recipients with dnDSAs who experienced acute AMR varied between 8 and 73% for (n ¼ 9) studies with a median follow-up <5 years, and between 5 and 54% for (n ¼ 7) studies with a median study follow-up !5 years. Compared with recipients without dnDSAs, the presence of dnDSAs was associated with an increased risk of acute AMR [RR 9.66; 95% CI 6.79-13.73, I 2 ¼ 9%, 16 studies, n ¼ 4174, evidence of publication bias (Egger's regression intercept P ¼ 0.002)] (Figure 2 ). The quality of the evidence for acute AMR was graded as moderate.
Chronic AMR and TG (12 studies, 4322 recipients). The included studies reported chronic AMR and TG interchangeably and/or with other diagnoses such as chronic allograft nephropathy, chronic rejection and chronic glomerulopathy. Figure S2 ).
Graft loss (29 studies, 9024 recipients). The proportion of recipients with dnDSAs who developed graft loss varied between 2 and 26% for (n ¼ 6) studies with a median followup <5 years and between 19 and 67% for (n ¼ 13) studies with a median study follow-up !5 years. Recipients with dnDSAs experienced an increased risk of graft loss [RR 4.95; 95% CI 3.81-6.43, I 2 ¼ 39%, 19 studies, n ¼ 5473, no evidence of publication bias (Egger's regression intercept P ¼ 0.615)] compared with recipients without dnDSAs (Figure 3) . Two studies reported death-censored graft loss [19, 20] . An increased risk of death-censored graft loss by two times was observed in recipients with dnDSAs compared with those without dnDSAs. The quality of evidence for graft loss was graded as low.
Mortality (14 studies, 3681 recipients). The proportion of recipients with dnDSAs who died varied between 2% and 18% for (n ¼ 3) studies with a median follow-up <5 years and between 4% and 14% for (n ¼ 4) studies with a median study follow-up !5 years. Recipients with dnDSAs experienced a 2-fold increased risk of mortality [RR 1.59, 95% CI 0.65-3.89, I 2 ¼ 52%, 7 studies, n ¼ 1674, no evidence of publication bias (Egger's regression intercept P ¼ 0.362)] compared with recipients without dnDSAs (Figure 3 ). The quality of evidence for mortality was graded as very low.
Meta-regression
Meta-regression was conducted to identify potential study level covariates that might explain variation in magnitude of estimates between studies for the outcomes of acute cellular Baseline risk calculated from largest study for given outcomes [17] with mean study follow-up time of 4 years. Quality of evidence for all outcomes downgraded to low due to only observational studies being available.
c Quality of evidence upgraded from low to moderate due to effect size and consistency (minimal heterogeneity), not upgraded to high due to likelihood of publication and outcome reporting bias.
d Quality of evidence downgraded from low to very low due to only two studies being available.
e Baseline risk calculated from largest study for given outcome [18] with median study follow-up time of 9 years. f Quality of evidence downgraded from low to very low due to imprecision (relative effect crosses point of clinical significance, i.e. 1.0).
FIGURE 3:
Association between dnDSAs and the risk of graft loss and mortality.
dnDSAs and renal transplant outcomes rejection, acute AMR, graft loss and mortality. Apart from the region of study (R 2 ¼ 0.50, P ¼ 0.005; Supplementary data, Figure S4 ) and type of donation (living versus deceased) (R 2 ¼ 1.00, P < 0.001; Supplementary data, Figure S5 ), there was no evidence that other factors modified the prognosis associated with dnDSAs including recipient age, gender, proportion of first transplants, HLA mismatches, MFI threshold, proportion of dnDSAs HLA Class II, study size, median follow-up time or year of publication (Supplementary data, Figure S3) .
The association between dnDSAs and acute cellular rejection was modified by the region in which studies were conducted. Studies originating from Asia reported an increased risk of any acute rejection (RR 7.24; 95% CI 2.90-18.09, 3 studies, n ¼ 928) in recipients with dnDSAs compared with recipients without dnDSAs. In comparison, there was an increased risk of any acute rejection in recipients with dnDSAs enrolled in studies originating from North American countries compared with recipients without dnDSAs (RR 2.12; 95% CI 1.60-2.81, 10 studies, n ¼ 2845). The association between dnDSAs and acute AMR was modified by the percentage of living donors included in the studies. Studies with a higher percentage of living donors reported a decreased risk of acute AMR compared with studies with a lower percentage of living donors (R 2 ¼ 1.00, P < 0.001; Supplementary data, Figure S5 ).
Sensitivity analysis
In studies where only LABScreen technology was used to identify the presence of pre-and post-transplant, the magnitude and direction of effects in the association between dnDSAs and transplant outcomes are similar to studies that included all laboratory technologies for the detection of dnDSAs. 2 ¼ 63%, 4 studies).
D I S C U S S I O N
This systematic review of 36 studies involving 10 535 kidney transplant recipients and 14 countries, has quantified the impact of dnDSAs on clinical outcomes after kidney transplantation, explored specific factors associated with worse outcomes and highlighted the uncertainties within the current evidence. Over a follow-up range between 1 and 9 years, 2-49% of kidney transplant recipients developed dnDSAs. Recipients with dnDSAs experienced an increased risk of both acute cellular rejection and AMR compared with those without dnDSAs. The presence of dnDSAs inferred a near 10 times increased risk of acute AMR with little statistically significant heterogeneity present in studies that reported AMR as an outcome, suggesting dnDSAs may be a potential predictive marker for AMR in kidney transplant recipients, independent of the variations in clinical practice observed. By contrast, there was substantial heterogeneity when assessing for acute cellular rejection and overall graft loss, reflecting the potential differences in immunosuppression use, timing and methods of DSAs detection, medication adherence and dissimilarity in organ allocation and clinical practices across different cohorts, which could not be explained using study level data. In addition, the magnitude and strength of the association between dnDSAs and acute cellular rejection and overall graft loss was considerably weaker than that of the relationship between dnDSAs and AMR, with notable inconsistency in the reporting of outcomes and followup duration. These data have also enabled the identification of additional factors that may influence the association between the development of dnDSAs and allograft outcomes. The magnitude of the risk of acute cellular rejection was modified by region. Studies originating from Asia reported higher rates of acute cellular rejection in the presence of dnDSAs than countries from North America. This may be explained by regional differences in choice of maintenance immunosuppression and use of T-cell depleting agents as induction therapy or reporting [21] . Furthermore, studies with higher proportions of living donor transplants reported lower rates of AMR, likely a reflection of improved immunological matching compared with deceased donor transplantation. The effect of differing laboratory techniques across studies was investigated using sensitivity analysis and meta-regression. Sensitivity analysis with studies employing LABScreen technology showed minimal differences in the magnitude of effects compared with the unrestricted analysis using all studies and any antibody detection technique. Metaregression using MFI thresholds as an explanatory factor did not explain heterogeneity across studies. This may be explained by the inter-laboratory variation between techniques or the lack of correlation between MFI and antibody strength [22] . Emerging laboratory techniques that assessed the ability of the dnDSAs to bind complement appeared to have deleterious effects on the allograft compared with non-complement binding dnDSAs [10, 17] . However, there were too few studies with sufficient power to conclude the clinical significance of this observed effect in this review.
Our study has several potential limitations. Recipients included in this study were of low immunological risk with the majority receiving their first transplant and 92% (33/36) of studies excluding recipients with pre-transplant DSAs. As such, our findings may not be generalizable to high-risk individuals. We were also unable to identify the specific DSAs characteristics that may be associated with the detrimental events such as AMR. Potential misclassification and inconsistency in reporting of binary outcomes such as acute cellular, antibody-mediated or mixed rejection [23] may have biased the interaction towards the null and under-reporting of relevant outcomes such as chronic AMR and TG have limited the certainty we could place on the observed estimates. Follow-up times, which contribute to heterogeneity in the measurement of time dependent events, were also highly variable between studies and most studies [50%, (15/30) ] reported median follow-up times of <5 years. Insufficient patient level data precluded detailed assessment of the relationship between HLA class differences and subtypes of dnDSAs with graft and patient outcomes.
To our knowledge, this is the first study that has systematically reviewed the literature of the impact of dnDSAs on the risk of rejection and renal allograft outcomes. Future research is needed to better define the predictors of dnDSAs development and the characteristics of dnDSAs that may adversely influence allograft outcomes. As patients developed higher proportions of dnDSAs against HLA Class II, there is potential for broad HLA antigen matching at the DR and DQ level and/or minimization of eplet mismatches at transplantation to reduce the overall risk of dnDSAs production [24] [25] [26] . While insufficient immunosuppression (either physician or patient derived) has been consistently linked with dnDSAs [27] , variations between classes or the optimal combinations of immunosuppression are yet to be established. Furthermore, postulated mechanisms such as the ability of dnDSAs to bind complement (e.g. C1q or C3d) [28, 29] , their immunoglobulin subclass [30, 31] , or the effect of electrostatic potential on the immunogenicity and antigenicity of the HLA molecule [32] may guide the identification of patients with the highest risk of adverse outcomes.
Consensus guidelines recommend routine screening for DSAs at least once for all patients during their first year after transplantation [33] . However, reliable, consistent and quality data supporting the frequency, modality, time points and costeffectiveness of screening and monitoring are insufficient to guide practice and confirm this as an appropriate clinical strategy. Routine screening for the development of dnDSAs has potential clinical benefits including early detection of antibody production and risk stratification for therapeutic intervention and monitoring. However, the success of screening measures depends on the availability of evidence to support effective treatments. While there are observational studies suggesting interventions such as plasmapheresis, eculizumab, bortezomib, rituximab and intravenous immunoglobulin are potentially efficacious in preventing acute rejection and graft loss in the presence of dnDSAs [19, 34] , randomized controlled trials are needed to address the paucity of evidence for prevention and treatment of adverse clinical events for patients who develop dnDSAs [35] .
C O N C L U S I O N
In conclusion, we have demonstrated an association between development of dnDSAs and excess risk of acute rejection (cellular and antibody mediated) and graft loss. However, the confidence placed in the observed estimates of association between dnDSAs and graft outcomes is at best moderate due to the limitations within the existing literature. Therapeutic strategies eliminating dnDSAs, tested by randomized controlled trials, and with sufficient power to assess longer term graft outcomes, are needed to establish the causal role of dnDSAs in graft survival and strengthen estimates of association.
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